The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
Gary Kelloff, M.D., NIH/NCI, (Co-Chair)
Emmett Schmidt, M.D., Ph.D., Merck (Co-Chair) Alex Snyder, Ph.D., Generate Biomedicines (SITC) (Co-Chair) Alexandre Akoulitchev, Ph.D., Oxford Biodynamics Jeff Allen, Ph.D., Friends of Cancer Research Daniel Auclair, Ph.D., AstraZeneca J. Carl Barrett, Ph.D., University of North Carolina Christopher Below, Ph.D., Biognosys Anna Berdine, M.S., Alamar Biosciences, Inc. Michelle Berny-Lang, Ph.D., NCI Donald A. Berry, Ph.D., MD Anderson Cancer Center Vikram Bhadrasain, M.D., NCI Gary Borzillo, Ph.D., Janssen Anita Boyapati, Ph.D., Regeneron Trixia Camacho, PharmD, BMS Claudio Carini, Ph.D., Kings College London Hearn Jay Cho, M.D., Ph.D., The Multiple Myeloma Research Foundation Caroline Chung, M.D., MD Anderson (QIBA-RSNA) Steven Cole, NCI Cecile Combeau, Ph.D., Sanofi Adam Corner, BioRad Michelle Douglas, Ph.D., Genentech Ed Driggers, Ph.D., General Metabolics Todd Druley. Ph.D., Danaher Jeff Ecsedy, Ph.D., Ikena Oncology Michael Espey, Ph.D., NCI Sharon Friedlander, Ph.D., Takeda Pharmaceuticals International, Inc. Steven Gendreau, Ph.D., Genentech Ida Grundberg, Ph.D., Olink Stanley R. Hamilton, M.D., City of Hope National Medical Center Sean Hanlon, Ph.D., NCI Lyndsay Harris, M.D., NCI Stephanie Hennek, Ph.D., PathAI Brandon Higgs, Ph.D., Genmab US, Inc. Steffan Ho, M.D., Ph.D., Pfizer Rob Iannone, M.D., Jazz Pharmaceuticals Peter Intile, SITC Taylor Jensen, Ph.D., LabCorp John Jessup, M.D., Institute for Bioscience and Biotechnology Research Jayaprakash Karkera, Ph.D., GlaxoSmithKline Morten Karsdal, Ph.D., Nordic Bioscience |
Ilan (Lanny) Kirsch, M.D., Adaptive Biotechnologies
Jessica Kuzma, Ph.D., SomaLogic/Standard Biotools Laura Lasiter. Ph.D., AstraZeneca Kate Lyden, Ph.D., VivoSense Derek McCartney, M.S., Biognosys Robert McCormack, Ph.D. Doug Mirsky, Ph.D., Digital Medicine Society Helen Moore, Ph.D., NIH/NCI Andrea Mortera, Empatica Larry Nagahara, Ph.D., John’s Hopkins University Jayant Narang, M.D., Takeda Michael O’Neal, M.D., Clario Mariaelena Occhipinti, Ph.D., Radiomics Geoff Oxnard, M.D., Eli Lily & Company Ketan Patel, Ph.D., Clarivate Snehal Patel, Ph.D., Association for Molecular Pathology Reena Philip, Ph.D., FDA/OCE Jelena Põlajeva, Ph.D., Clarivate Vladimir Popov, Ph.D., FNLCR/NCI Scott Knowles Pruitt, M.D., Ph.D.,Merck Elizabeth Punnoose, Ph.D., Genentech Anita Reddy, Ph.D., Amgen Michael Reeder, Ph.D., Johnson & Johnson Henry Rodriguez, Ph.D., NIH/NCI Vanessa Rodrik-Outmezguine, Ph.D., Eli Lilly & Company Marijana Rucevic, Ph.D., Olink Proteomics Mert Sahin, Ph.D., Durin Technologies Lawrence Schwartz, M.D., Memorial Sloan Kettering Maggie Scully, Ph.D.,Frederick Natl. Lab. For Cancer Research Christine Sewany, Ph.D., Danaher Howard Spiegel, Olink Proteomic Magadelena Thurin, Ph.D., NIH/NCI Peter Ujhazy, M.D., Ph.D., NIH/NCI Tamar Uziel, Ph.D., AbbVie Sarah Valentine, Digital Medicine Society Megann Vaughn, M.B.A., LabCorp Wim Vos. Ph.D., Radiomics Tony Wagner, Ph.D., Jazz Pharmaceuticals Joel Wommack, Ph.D., SomaLogic Rebekah Zinn, Ph.D., FDA |